Researchers identified a mechanism by which APOE4 may contribute to cerebrovascular damage and amyloid accumulation in Alzheimer's disease and reversed related changes in mice. Separately, Gilead's anitocabtagene autoleucel produced responses in an early-stage multiple myeloma trial, while a new imaging approach identified senescent cells without destroying them.
An early analysis of real-world data found patients with recent weight gain were more likely to achieve more than 10% weight loss with oral Wegovy. Separately, a mouse study found sensory neurons retain a memory of allergen exposure that may influence responses to later exposures.
A study of more than 3.3 million people found a rare inherited EGFR T790M mutation was associated with substantially higher lung cancer risk, particularly among never-smokers. Separately, a randomized trial found intrauterine mepivacaine reduced pain during intrauterine device insertion in women who had never given birth.
Two late-stage trials found Opus Genetics' phentolamine eye drops improved night vision, glare and halo symptoms in patients with impaired low-light visual acuity. Separately, a survey of U.S. cancer centers found widespread shortages of key generic oncology drugs, including ifosfamide, carboplatin and Bacillus Calmette-Guérin.
At the European Respiratory Society Congress, AstraZeneca's tozorakimab reduced moderate-to-severe COPD exacerbations in two late-stage trials. Separate studies found high-dose influenza vaccination lowered hospitalization risk in older adults with chronic lung disease and identified brain-structure differences in patients with severe type-2 asthma.
Today we feature two early studies, one that points toward a possible way to prevent nerve damage from chemotherapy drugs and another that reveals previously unrecognized effects of bacteria that are known to make adults very sick but that were thought to be harmless to babies.
Researchers identified 36 genes linked to obsessive-compulsive and chronic tic disorders, revealing shared biological pathways and potential targets for novel therapeutics. Separately, blocking the mitochondrial protein EFHD1 reduced fatty liver injury and scarring in preclinical models, supporting a potential drug development strategy.
